CCRA® Preparation: Monitoring Decisions, Participant Protection, and Reliable Data Study Guide

Apply it

A site proposes moving the primary functional assessment from before dosing to immediately afterward for convenience. The CRA identifies the changed relationship to treatment and seeks protocol-directed resolution before the site adopts the new schedule.

Apply it

An updated brochure describes a newly recognized laboratory abnormality. The CRA checks that the investigator received and reviewed it, then verifies whether related sponsor instructions, protocol changes, or participant information updates require action at the site.

Apply it

A screening result falls outside the permitted range, but the investigator expects it to normalize. The CRA checks whether the protocol permits repeat testing and verifies qualifying evidence before enrollment rather than accepting an anticipated future result.

Apply it

A coordinator can see tomorrow's treatment assignments before selecting eligible participants for enrollment. Although the sequence was computer generated, the CRA identifies compromised concealment and escalates the access problem for investigation and corrective action.

Apply it

A placebo comparison may meet the exception when compelling methodological reasons require it and withholding proven care creates no additional risk of serious or irreversible harm. By contrast, removing proven treatment that prevents irreversible injury fails the harm criterion, even if placebo would produce a clearer treatment difference.

Apply it

A study switches participants to the comparator while the first treatment's effect is expected to persist. The CRA flags the design concern because a second-period outcome could reflect both interventions rather than the current intervention alone.

Apply it

A participant stops study treatment but permits follow-up. Because the trial targets a treatment-policy effect at six months, the CRA verifies continued endpoint collection under the protocol rather than assuming treatment discontinuation ends all study assessments.

Apply it

A participant reports mild chest discomfort that leads to unplanned inpatient admission for evaluation. The CRA checks the hospitalization details and investigator assessment because the mild symptom description does not remove the potential serious-event classification.

Apply it

The reference safety information lists transient mild liver-enzyme increases, but a participant develops suspected product-related liver failure requiring admission. The CRA ensures the actual clinical severity reaches sponsor safety personnel rather than treating the event as expected from the symptom category alone.

Apply it

The investigator reasonably becomes aware of a participant's hospitalization, but the discharge diagnosis is pending. The CRA verifies immediate sponsor reporting with the investigator's causality assessment and follows up for the diagnosis and other necessary clinical details as they become available.

Apply it

A signed form is present, but the participant explains that the research infusion was described as guaranteed treatment. The CRA investigates the consent discussion and escalates the misunderstanding rather than considering the signature sufficient evidence of valid consent.

Apply it

A newly identified risk changes recommended monitoring and may affect willingness to continue. The CRA verifies approved participant information, timely communication to affected participants, and documentation of renewed consent where required rather than waiting for each participant's next routine visit.

Apply it

A participant enrolled with parental permission reaches legal adulthood while follow-up continues. The CRA checks the site's process for obtaining the participant's own informed consent for continued participation instead of relying indefinitely on the original parental permission.

Apply it

An emergency physician states that the assigned treatment will determine immediate management. The CRA verifies that the site uses the emergency access procedure promptly and documents the disclosure, while protecting other participants' assignments and blinded assessments wherever feasible.

Apply it

A recruitment plan promises a guaranteed therapeutic benefit and pays the entire visit allowance only after the final visit. The CRA identifies both the misleading claim and completion pressure for revision and required ethics review before use.

Apply it

A participant declines further dosing because of travel burden but is willing to complete telephone assessments. The CRA verifies that the site records treatment discontinuation separately from withdrawal of follow-up permission and follows the protocol for the remaining activities.

Apply it

A required safety assessment was missed before dosing, although the participant feels well. The CRA verifies investigator evaluation of the participant, documents the departure, and checks appropriate reporting and corrective action rather than dismissing it because no injury is apparent.

Apply it

An investigator has a disclosed financial interest, and several source entries appear copied with impossible dates. The CRA treats conflict management and suspected record falsification as related but separate issues, documenting the anomalies and escalating them through the sponsor's established process.

Apply it

A sponsor has approved a protocol internally, but the site lacks documented favorable ethics review. The CRA identifies the missing independent review and prevents study initiation activities from being mistaken for authorization to enroll participants at that site.

Apply it

The site files an approval letter for consent version two but prepares version three for enrollment. The CRA checks whether version three was included in a later favorable decision before accepting it as an approved participant-facing document.

Apply it

An amendment changes eligibility, and the sponsor distributes it today. The site's ethics decision is still pending. The CRA verifies that screening continues under the currently authorized requirements until approvals and implementation conditions for the amendment are met.

Apply it

A clinician stops a protocol-required infusion immediately after identifying a dangerous equipment malfunction. The CRA verifies documentation of the hazard and action, appropriate notifications, and review of whether a broader procedure change is needed before similar infusions resume.

Apply it

The sponsor first receives a report identifying the participant, reporter, suspect product, and a life-threatening unexpected event with reasonably suspected causality. The seven-calendar-day clock starts with that knowledge even though the final diagnosis is pending. The site cannot use the sponsor's reporting window to delay its own immediate SAE notification.

Apply it

An ethics committee requests revised participant wording as a condition of continuing favorable review. The CRA checks the site's response, the committee's subsequent decision, and implementation of the approved wording rather than accepting a submission receipt as final clearance.

Apply it

A sponsor suspends dosing after a safety signal. The CRA verifies that the site receives clear instructions, informs the required oversight bodies, contacts affected participants appropriately, and maintains the specified safety follow-up instead of treating the suspension as immediate administrative closure.

Apply it

A global procedure proposes one retention period, while the site's applicable requirement is longer. The CRA identifies the discrepancy for resolution and verifies a compliant retention plan rather than assuming a harmonized guideline overrides the binding local obligation.

Apply it

A trial's primary outcome depends on an assessment before rescue treatment. The team identifies correct assessment timing and rescue-use documentation as critical factors, then designs scheduling checks and monitoring indicators around those processes before enrollment begins.

Apply it

A trial uses remote review for data trends but requires targeted on-site assessment of consent practices after irregularities arise. The CRA follows the revised plan and documents why the additional activity addresses a risk that listings alone cannot resolve.

Apply it

One site reports almost no adverse events despite exposure and participant characteristics similar to other sites. The CRA reviews reporting practices and source information to determine whether the pattern reflects real differences, incomplete elicitation, or delayed entry.

Apply it

A coordinator repeatedly misses clinically significant laboratory alerts while the investigator signs forms weeks later. The CRA escalates the ineffective review process and verifies an oversight arrangement that ensures timely medical assessment rather than merely updating the delegation list.

Apply it

A laboratory vendor sends critical alerts to the CRO, but the CRO believes the sponsor forwards them to investigators. The CRA identifies the unassigned handoff and escalates it so responsibilities, confirmation steps, and oversight are explicitly established.

Apply it

A site identifies many potentially eligible patients but cannot obtain the protocol's time-sensitive imaging outside ordinary clinic hours. The CRA evaluates the practical procedure gap and possible compliant arrangements before recommending the site for participation in the study.

Apply it

An experienced site has an adequate pharmacy but lacks validated access for the study's endpoint device. The CRA records the unresolved dependency and verifies a suitable solution before treating the site's past trial experience as sufficient evidence of readiness.

Apply it

Several visits miss a timed sample. Investigation shows that the scheduling system displays only the visit date and omits the required collection interval. The CRA supports correction of the scheduling workflow instead of attributing every miss solely to individual forgetfulness.

Apply it

A site installs a second check after repeated dispensing errors. The CRA verifies implementation and reviews later dispensing records to establish whether the new check actually prevents mismatches, rather than closing the finding when staff sign the revised procedure.

Apply it

Before an inspection, a site discovers an unsigned historical worksheet. The CRA advises transparent handling through the site's documentation process and preservation of the original record rather than creating a falsely contemporaneous signature to make the file appear complete.

Apply it

A site repeatedly doses participants without required safety results despite prior corrective actions. The CRA promptly escalates the ongoing critical failure and verifies sponsor-directed protective measures rather than waiting for the next scheduled monitoring report to summarize the pattern.

Apply it

All staff attend initiation, but the person responsible for randomization cannot access the allocation system. The CRA records the gap, verifies access and task competence, and ensures enrollment authorization reflects actual readiness rather than attendance alone.

Apply it

A newly hired coordinator has GCP training but has never used the study's assessment device. The CRA verifies task-specific preparation and an appropriate delegation arrangement before the coordinator independently performs participant assessments that contribute to the endpoint.

Apply it

During an interim visit, the CRA finds unresolved safety queries discussed by telephone the previous month. The follow-up record identifies the remaining information, responsible investigator, expected completion, and escalation route, allowing the next review to assess actual resolution.

Apply it

A refrigerator alarm shows an overnight excursion affecting three kits. The CRA checks that the kits are segregated against use, the event is documented, and an authorized stability assessment determines disposition before the pharmacy releases any affected kit.

Apply it

A site received 240 tablets, dispensed 150, and has 80 unused tablets in storage, with no other stock movements. The expected unused balance is 90, so the CRA investigates a ten-tablet discrepancy using the receipt, dispensing, and inventory records.

Apply it

The randomization system assigns kit 406, but the prepared bag contains kit 460. The CRA verifies that the discrepancy is resolved before dispensing and that the process identifies why the transposition escaped the site's intended checking steps.

Apply it

A pharmacy proposes discarding expired study kits during a routine cleanout. The CRA verifies sponsor instructions, completes necessary reconciliation, and obtains appropriate disposition evidence before the kits leave controlled storage or are destroyed through an authorized process.

Apply it

The primary endpoint scale was used after its required calibration date. The CRA identifies the affected assessments and obtains a documented evaluation of measurement reliability and corrective action rather than assuming later recalibration retrospectively validates all earlier results.

Apply it

A pharmacokinetic sample is required 60 minutes after dosing, with an allowed range of 55 to 65 minutes. Dosing occurs at 09:10 and collection at 10:18. Elapsed time is 68 minutes: eight minutes after the target and three minutes beyond the allowed upper limit. The CRA verifies preservation of both actual timestamps and documentation and assessment of the out-of-window collection.

Apply it

A laboratory receives a tube whose code differs from the accompanying requisition. The CRA verifies investigation against original collection and shipment records, preserving the discrepancy and resolution rather than allowing staff to relabel the tube based on memory.

Apply it

Returned tablets suggest missed doses, while the diary reports perfect adherence. The CRA verifies that the site discusses the discrepancy with the participant, documents available facts and barriers, and follows the protocol rather than editing one source to match the other.

Apply it

A site discovers that required follow-up calls were omitted from its budget. The CRA routes the contractual issue for resolution while verifying that agreed participant safety follow-up continues through an appropriate plan rather than being silently discontinued.

Apply it

The investigator file contains an amendment but lacks evidence of site approval and implementation. The CRA reconciles the relevant sponsor and site records, identifies the missing evidence, and verifies an accurate resolution rather than simply adding another copy of the amendment.

Apply it

An approved amendment adds a predose laboratory check. The CRA verifies revised visit tools, staff training, laboratory arrangements, and the applicable implementation date before the first affected visit, rather than assuming distribution of the amended protocol has changed practice.

Apply it

All visits are complete, but product destruction confirmation and a serious-event follow-up remain outstanding. The CRA records responsible parties and required resolution, verifies continuing safety obligations, and avoids treating a scheduled close-out meeting as proof that every obligation has ended.

Apply it

An eCRF laboratory value matches the laboratory report, but no timely investigator assessment of the critical result is documented. The CRA recognizes successful transcription verification alongside an unresolved clinical review process that requires separate investigation and follow-up.

Apply it

A coordinator notices that yesterday's visit time was entered incorrectly. The site corrects the entry through the authorized process, preserving the original value and change history, instead of replacing the page or changing the date to conceal the late correction.

Apply it

A recorded stop date precedes the start date for the same medication. The CRA asks the site to verify both dates against source records and correct or explain the discrepancy, rather than instructing the coordinator to move the stop date forward.

Apply it

A laboratory interface transfers glucose values but drops the units. The CRA identifies that numerical agreement alone is insufficient and verifies correction of the interface and evaluation of affected records before the data are considered interpretable.

Apply it

A site offers the CRA a coordinator's login to review electronic records. The CRA seeks an authorized individual access arrangement with suitable permissions rather than using shared credentials that would attribute the review or changes to someone else.

Apply it

A site plans to retire the electronic system containing original trial records. The CRA verifies a suitable preservation and access plan, including relevant metadata and readability, before system retirement prevents future reconstruction of the study's conduct.

Apply it

The safety database records a hospitalization, but the clinical database contains no corresponding event. The CRA facilitates source-based review and appropriate updates so both safety reporting and study analyses account for the event without creating an unsupported duplicate.

Apply it

Before lock, the CRA identifies an unresolved primary endpoint query and missing investigator review. At the same time, site staff request interim treatment comparisons. The CRA supports completion of required review while maintaining the defined restriction on comparative interim information.